JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

TMO

477.27

-1.09%↓

ISRG

500.18

+0.72%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

TMO

477.27

-1.09%↓

ISRG

500.18

+0.72%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

TMO

477.27

-1.09%↓

ISRG

500.18

+0.72%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

TMO

477.27

-1.09%↓

ISRG

500.18

+0.72%↑

JNJ

167.29

-0.43%↓

NVS

116.69

-0.32%↓

ABT

128.65

+0.56%↑

TMO

477.27

-1.09%↓

ISRG

500.18

+0.72%↑

Search

Sana Biotechnology Inc

Cerrado

SectorSalud

4.35 -1.58

Resumen

Variación precio

24h

Actual

Mínimo

4.31

Máximo

4.69

Métricas clave

By Trading Economics

Ingresos

-320K

-49M

Empleados

194

EBITDA

-1.8M

-47M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+120.22% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

675M

1.1B

Apertura anterior

5.93

Cierre anterior

4.35

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

157 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Sana Biotechnology Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 jul 2025, 23:57 UTC

Adquisiciones, fusiones, absorciones

EQT: To Spend Y407.82B for Tender Offer

29 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

EQT: Tender Offer Price Is Y5,700 a Share

29 jul 2025, 23:54 UTC

Adquisiciones, fusiones, absorciones

EQT To Start Tender Offer for Fujitec

29 jul 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

29 jul 2025, 23:36 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Decision -- Market Talk

29 jul 2025, 22:57 UTC

Charlas de Mercado

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

29 jul 2025, 22:50 UTC

Charlas de Mercado

Mondelez Warns of Price Increases in North America -- Market Talk

29 jul 2025, 22:44 UTC

Adquisiciones, fusiones, absorciones

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

29 jul 2025, 22:41 UTC

Adquisiciones, fusiones, absorciones

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

29 jul 2025, 22:35 UTC

Ganancias

IGO Maintains Nova Life of Mine Production Guidance

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

29 jul 2025, 22:35 UTC

Ganancias

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

29 jul 2025, 22:34 UTC

Ganancias

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

29 jul 2025, 22:34 UTC

Charlas de Mercado
Ganancias

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

29 jul 2025, 22:33 UTC

Ganancias

IGO Had A$279.7 Million of Cash at End-June

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Underlying Free Cash A$2.4 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO FY Sales Revenue A$512.5 Million

29 jul 2025, 22:33 UTC

Ganancias

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO FY Nickel Production 17,173 Tons

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

29 jul 2025, 22:32 UTC

Ganancias

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

29 jul 2025, 22:31 UTC

Charlas de Mercado
Ganancias

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

29 jul 2025, 22:31 UTC

Ganancias

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

29 jul 2025, 22:31 UTC

Ganancias

IGO FY Spodumene Production 1.48 Million Tons

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

29 jul 2025, 22:30 UTC

Ganancias

IGO 4Q Underlying Ebitda A$62 Million

29 jul 2025, 22:22 UTC

Ganancias

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Comparación entre iguales

Cambio de precio

Sana Biotechnology Inc Esperado

Precio Objetivo

By TipRanks

120.22% repunte

Estimación a 12 meses

Media 9.8 USD  120.22%

Máximo 15 USD

Mínimo 5 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sana Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

6

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.68 / 1.87Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

No Evidence

Sentimiento

By Acuity

157 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.